Blenrep approval date?

See the DrugPatentWatch profile for Blenrep

When was Blenrep (belantamab mafodotin) approved?

Blenrep (belantamab mafodotin) was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including specific prior treatments (including an anti-CD38 antibody and a proteasome inhibitor and an immunomodulatory agent). [1]

Was the approval the first or a later (expanded/updated) approval?

The FDA approval cited above is the original FDA approval year for Blenrep. The specific indication and label details have been updated over time due to trial results and regulatory actions, but the approval date you’re asking for corresponds to the initial FDA approval in 2020. [1]

Which country’s “approval date” do you mean?

“Approval date” can differ by regulator and country (for example, FDA vs. EMA). If you tell me the region you need (U.S., Europe/EMA, UK, etc.), I can give the exact regulator-specific approval date.

Source

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761305